SXT drug elimination

How is your #drug eliminated? #FDA and other #regulatory agencies recommend conducting excretion studies proactively, i.e., pre-IND, to gather appropriate data to inform study design and dosing considerations for first in-human (FIH) #clinicaltrials. This primarily refers to animal #massbalance studies, but biliary excretion may play a role in the compound’s elimination. This can be investigated via Bile Duct Cannulation (BDC) in a Biliary Excretion study in cases where >20% of radioactivity is detectable in feces during the radiolabeled animal mass balance study. Through our partners at the #DrugDevelopment Solutions Center, we can offer you top-of-the-line specialists to handle this critical component of your nonclinical work. Find out more about this service: